Abstract: The present invention relates to a detector matrix for detecting at least one analyte in a sample, preferably a sample of a body fluid, comprising at least one enzyme active in the presence of said at least one analyte and at least one indicator reagent changing at least one optical property dependent on the activity of said enzyme, wherein said detector matrix further comprises up-converting phosphor particles, preferably UV-emitting up-converting phosphor particles. The invention further relates to a test element and a test device for detecting at least one analyte in a sample comprising the detector matrix of the invention, as well as to a method for the manufacture of a detector matrix, a method for the manufacture of a test element, and to a method for detecting an analyte in a sample, comprising contacting a detector matrix according to the invention with a sample suspected to comprise said analyte.

Abstract: In one arrangement, a cartridge includes a cartridge body defining a holding compartment, first and second fractioning compartments, and a number of flow channels formed within the cartridge body. A predetermined quantity of fluid can be held in the holding compartment when the cartridge body is held in a first orientation, and can be poured from the holding compartment to the first fractioning compartment by rotating the cartridge body about a predefined rotation axis to a second orientation, spilling the fluid from the holding compartment to the first fractioning compartment through one of the flow channels. The first fractioning compartment is such that when the cartridge body is in the second orientation, not all of the fluid can be contained in the first fractioning compartment, and fluid that overflows the first fractioning compartment flows through a second flow channel to the second fractioning compartment.

Abstract: Methods of increasing the capture efficiency of a microfluidic device for a target reagent, without additional complications to the design of existing microfluidic devices, and more particularly methods of increasing the capture efficiency of a microfluidic device for magnetic microbeads within a microfluidic channel using sequentially switched electroosmotic flows.

Abstract: A method for assessment of neural function by establishing an analysis module is revealed. The first step of the method is to capture images of the cultured cells with a plurality of fluorescence labeling by a fluorescence microscopy system for image analysis. The cultured cells include neurons and non-neuronal cells. Then select neurons with neurites having fluorescence labeling and exclude non-neuronal cells according to an area and a fluorescence intensity of nucleus. Also calculate an area of the neuronal cell body, a length of the neurites and a number of processes and branches to verify outgrowth of the neurites of the neurons. Next calculate a number of synaptic puncta having fluorescence labeling on the area of the neurites having fluorescence labeling defined in Step 2 to verify formation of the synaptic puncta of the neurons for assessment of neural function.

Abstract: An electrical biosensor for use with a reader is provided and can include an electrical component configured such that the coupling of a targeted substance to a surface of the electrical component changes an electrical characteristic of the electrical component. A protein immobilization structure can be disposed on the surface and can include an array of functionalized structures for interacting with a substance in a sample of a bodily fluid. Each functionalized structure can include a protein capable of binding to a targeted chemical substance or substance in the sample whereby an electrical reading can be obtained by a reader to determine the concentration level of the targeted substance in the sample.

Abstract: Microspheres, populations of microspheres, and methods for forming microspheres are provided. One microsphere configured to exhibit fluorescent and magnetic properties includes a core microsphere and a magnetic material coupled to a surface of the core microsphere. About 50% or less of the surface of the core microsphere is covered by the magnetic material. The microsphere also includes a polymer layer surrounding the magnetic material and the core microsphere. One population of microspheres configured to exhibit fluorescent and magnetic properties includes two or more subsets of microspheres. The two or more subsets of microspheres are configured to exhibit different fluorescent and/or magnetic properties. Individual microspheres in the two or more subsets are configured as described above.

Abstract: The present invention relates to a nanoparticle heterodimer in which Raman-active molecules are located at a binding portion of the nanoparticle heterodimer, and more particularly, to a core-shell nanoparticle heterodimer comprising: a gold or silver core having a surface to which oligonucleotides are bonded; and a gold or silver shell covering the core. In addition, the present invention relates to the core-shell nanoparticle dimer, to a method for preparing same, and to the use thereof.

Abstract: Provided herein are methods, compositions, and devices for the identification and quantification of analytes, such as nucleic acids, proteins, cells or other biological samples. The methods, compositions, and devices are suited for accurate, portable analysis of small amounts of analyte.

Abstract: The present invention proposes a new structuring method for producing slices comprising fiber fragments through a series of steps of functionalizing fibrous materials, bundling the functionalized fibrous materials, and thinly cutting the bundle. Based on the fiber bundle fragments, ultra-low cost multiplexed bioassay platforms are developed.

Abstract: The present invention relates to a biomolecular measurement system (1), which enables to measure the intermolecular forces arising from the interaction between two biomolecules or the intramolecular forces within a single biomolecule by using an atomic force microscope (AFM). In the present invention, the cantilever (2) is moved only when the actuator (4) moves the magnetic nanowire (3) and thus moves the molecule attached to the end of the magnetic nanowire (3). Since the cantilever (2) is not moved, fluctuation and disturbance is not created in the liquid containing the biomolecules. Thus, the measurements are made more accurately and with higher resolution. Additionally, by means of the actuator (4), the biomolecules are enabled to be moved upon exertion of magnetic force at any coordinate on x, y and z axes on the nanowire (3), or exertion of torque on two axes.

Abstract: The present invention provides devices and systems for use at the point of care. The methods devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device are modular to allow for flexibility and robustness of use with the disclosed methods for a variety of medical applications.

Abstract: This invention relates generally to devices and methods for performing optical and electrochemical assays and, more particularly, to test devices, e.g., cartridges, methods and systems, wherein the test devices have an entry port configured to receive a test sample into a holding chamber; a first conduit having at least one lateral flow test strip; and a displacement device, such as a pneumatic pump, configured to move a portion of said test sample from said holding chamber into said first conduit. The present invention is particularly useful for performing immunoassays and/or electrochemical assays at the point-of-care.

Abstract: A micro-resonator and fiber taper based sensing system, which uses mode splitting or frequency shift methods and polarization measurements for particle sensing.

Abstract: This detection device has a holder and a heating unit. The holder holds a detection chip that has the following: a prism that has an incidence surface and a film-formation surface; a metal film formed on said film-formation surface; trapping bodies laid out on the surface of said metal film; and a substrate that is laid out on the surface of the metal film, and together with the metal film, forms a liquid collection section in which a liquid is collected. The heating unit heats at least one of the substrate, the prism, and the metal film either while in contact therewith or without contacting same. Also, the heating unit is positioned so as to avoid the path that excitation light takes from an excitation-light emission unit to the abovementioned incidence surface.

Abstract: The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borreliae, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies.

Abstract: Methods for aiding in the diagnosis of disorders including, but not limited to, PDDs (Pervasive Development Disorders), Dysautonomic disorders, Parkinson's disease and SIDS (Sudden Infant Death Syndrome). In one aspect, a diagnosis method comprises analyzing a stool sample of an individual for the presence of a biological marker (or marker compound) comprising one or more pathogens, which provides an indication of whether the individual has, or can develop, a disorder including, but not limited to, a PDD, Dysautonomia, Parkinsons disease and SIDS. Preferably, the presence of one or more pathogens is determined using a stool immunoassay to determine the presence of antigens in a stool sample, wherein such antigens are associated with one or more pathogens including, but not limited to, Giardia, Cryptosporidium, E. histolytica, C. difficile, Adenovirus, Rotavirus or H. pylori.

Abstract: The purpose of the present invention is to provide a method of purification and preparation of cultured corneal endothelial cells, and in particular, to provide cell surface markers for use in corneal endothelial cells not including transformed cells. Provided are cell markers for distinguishing normal cells and transformed cells, in particular normal and transformed corneal endothelium cells. These cell markers relate to specific cell surface markers, for example, to a normal corneal endothelial surface marker such as CD166, and a transformed cell surface marker such as CD73. By using the transformed cell surface marker such as CD73 to remove transformed cells by sorting, it becomes possible to improve purity of a normal cultured corneal endothelium. By using normal corneal endothelial surface marker such as CD166, or by combined use with the transformed cell surface marker, it becomes possible to provide a means for verifying the purity of a prepared corneal endothelium.

Abstract: This document provides methods and materials involved in assessing immune system profiles. For example, methods and materials for performing flow cytometry to determine the number of CD4+ lymphocytes, CD8+ lymphocytes, regulatory T cells, B cells, NK cells, granulocytes, CD14+HLA-DRlo/neg monocytes, and/or CD86+ monocytes per unit volume (e.g., cells per ?L or mL) of whole blood (e.g., fresh, un-manipulated whole blood) obtained from a mammal (e.g., a human) are provided.

Abstract: The present invention also provides infectious DNA clones, biologically functional plasmid or viral vector containing the infectious nucleic acid genome molecule of Torque teno sus virus (TTsuV). The present invention also provides methods for diagnosing TTsuV infection via immunological methods, e.g., enzyme-linked immunoabsorbent assay (ELISA) and Western blot using PTTV specific antigens for detecting serum PTTV specific antibodies which indicate infections TTsuV1, TTsuV2, and individual TTsuV1 genotypes.

Abstract: The present invention provides HA polypeptides (e.g., H1 HA polypeptides) that bind to umbrella-topology glycans, and reagents and methods relating thereto. The present invention provides binding agents that bind to HA polypeptides (e.g., H1 HA polypeptides), and reagents and methods relating thereto. The present invention provides interfering agents that inhibit the binding of HA polypeptides (e.g., H1 HA polypeptides) to HA receptors, and reagents and methods relating thereto. The present invention provides compositions and methods for treating, preventing, and/or diagnosing influenza infection utilizing HA polypeptides, HA polypeptide binding agents, HA polypeptide interfering agents, and/or vaccine compositions comprising any of the foregoing.

Abstract: The detection and quantification of nucleic acid sequences can be done using template catalyzed TARA transfer reactions without enzyme and PCR. It comes with the novel chemistry platform technology using Template Assisted Rapid Assay (TARA), an enzyme-free, PCR-less and rapid transfer reaction assay directly from samples from nasopharyngeal swab, nasal aspirate, oropharyngeal swab or blood. The procedures of the detection and quantification of nucleic acid sequences include utilizing two or more oligonucleotide probes that reversibly bind a target nucleic acid in close proximity to each other and possess complementary reactive TARA reaction moieties. In addition, various methods, reagents, and kits for detecting and quantifying nucleic acid sequences and for determining the sequence of nucleic acids are provided.

Abstract: A lateral flow assay is capable of detecting and differentiating viral and bacterial infections. A combined point of care diagnostic device tests markers for viral infection and markers for bacterial infection, to effectively assist in the rapid differentiation of viral and bacterial infections. In some preferred embodiments, bimodal methods and devices determine if an infection is bacterial and/or viral. A dual use two strip sample analysis device includes a first lateral flow chromatographic test strip to detect MxA and a low level of C-reactive protein and a second lateral flow chromatographic test strip to detect high levels of C-reactive protein. In some preferred embodiments, the sample is a fingerstick blood sample.

Abstract: Studies in mouse models of Fragile X and preliminary studies in human youth demonstrate that ERK1/2 is biomarker useful to monitoring the treatment of people diagnosed with ASD. Results reported herein demonstrate that acamprosate has the ability to reduce levels of ERK1/2 activation associated with many of the symptoms of ASD. Accordingly, in addition to its utility as a diagnostic marker for ASD ERK1/2 activation levels can be used to monitory patients treated with acamprosate.

Abstract: Methods for characterizing the near terns risk of experiencing a major adverse cardiac event in a patient presenting with chest pain are provided. In one embodiment the method comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained. from the patient. In another embodiment, the method comprises determining the level of MPO mass in a bodily sample obtained from the patient. In another embodiment, the method comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the patient. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, chlorotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation product.

Abstract: A laboratory method and system used to isolate and analyze O-linked oligosaccharides from glycoproteins that uses non-reductive ?-elimination (NBRE). The method including the step of providing a predetermined amount of solution and then passing it through an ion exchange resin. The method further includes collecting a second solution off of the ion exchange resin and adding a predetermined amount of sodium hydroxide to form a third solution. The third solution is allowed to stand for a set amount of time at a particular temperature. The third solution is then washed through an ion exchange cartridge in the ammonium form. The collected fourth solution is evaporated and pushed through a sodium form resin prior to being analyzed for its composition.

Abstract: Provided is a treatment method for damaging an erythrocyte and a leukocyte while suppressing damage to cells other than blood cells present in blood. In an embodiment, the disclosure relates to a method for treating a sample containing blood components, the method including mixing a sample containing blood components with a surfactant A, where the surfactant A is a nonionic surfactant represented by General formula R1—O-(EO)n-R2 (I).

Abstract: Antibodies, and antibody pairs, that bind and specifically detection pre-Haptoglobin-2, and methods for their use, are provided.

Abstract: Disclosed are methods of predicting whether a subject's metastatic breast cancer is stable or progressive are provided. Such methods may include measuring T cell subsets in a fluid sample of the subject; and predicting whether the subject's metastatic breast cancer is likely to be stable or progressive when there is an elevated ratio of the T cell subsets. Also disclosed are methods of treating metastatic breast cancer by a conservative therapy or an aggressive therapy based on the determination of a stable or progressive cancer.

Abstract: Provided herein are methods, e.g., computer-implemented methods or automated methods, of evaluating a cancer sample, e.g., a prostate tumor sample, from a patient. Also provided are biomarker panels for prognosticating prostate cancer. Also provided are methods of treating prostate cancer by identifying aggressive prostate cancer or prostate cancer that may have lethal outcome.

Abstract: The present invention provides methods for predicting response to a hormone-directed therapy or chemotherapy in a prostate cancer (PCa) patient comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characterization of nucleated cells in a blood sample obtained from the patient to identify and enumerate circulating tumor cells (CTC); (b) individually characterizing genotypic, morphometric and protein expression parameters to generate a profile for each of the CTCs, and (c) predicting response to hormone-directed therapy in the prostate cancer PCa patient based on said profile. In some embodiments, the methods comprise repeating steps (a) through (c) at one or more timepoints after initial diagnosis of prostate cancer to sequentially monitor said genotypic, morphometric and protein expression parameters.

Abstract: The present invention relates to diagnosis of ovarian cancer using lysophosphatidylcholine (16:0) and homocysteic acid, which are low-mass ions present in biological samples. The use of the present invention enables ovarian cancer to be diagnosed in a cost-effective, rapid and accurate manner. Thus, it is expected that the present invention will be effectively used to diagnose and treat ovarian cancer.

Abstract: The present invention relates to PI(4,5)P2 and more particularly to use of enzymes that metabolize and regulate the PI(4,5)P2 levels as a as a target for cancer treatment. Furthermore, measuring the level of PI(4,5)P2 or the degree of turnover of PI(4,5)P2 in cancer cells is an important diagnostic tool.

Abstract: The present disclosure provides a quenching dye with an anthraquinone structure, which has a broad and high absorption spectrum in the visible and near-infrared wavelength regions and exhibits high stability and superior solubility in aqueous conditions. A quenching dye composition containing the anthraquinone compound according to the present disclosure as an active ingredient can be widely used in the field of optical molecular imaging to observe the movement of a biomolecule because it can easily label a biomolecule manipulated in an aqueous buffer.

Abstract: Water soluble light harvesting multichromophores that have an ultraviolet absorption maximum are provided. In some embodiments, the multichromophores include a conjugated segment including a fused 6-5-6 tricyclic co-monomer and a UV absorbance-modifying co-monomer. The multichromophores may include an acceptor chromophore covalently linked to the multichromophore in energy-receiving proximity therewith. In some embodiments, a specific binding member is covalently linked to the multichromophore. Also provided are methods of evaluating a sample for the presence of a target analyte and methods of labelling a target molecule using compositions including the light harvesting multichromophores. Kits and systems for practicing the subject methods are also provided.

Abstract: Methods and compositions are provided that include a multichromophore and/or multichromophore complex for identifying a target biomolecule. A sensor biomolecule, for example, an antibody can be covalently linked to the multichromophore. Additionally, a signaling chromophore can be covalently linked to the multichromophore. The arrangement is such that the signaling chromophore is capable of receiving energy from the multichromophore upon excitation of the multichromophore. Since the sensor biomolecule is capable of interacting with the target biomolecule, the multichromophore and/or multichromophore complex can provide enhanced detection signals for a target biomolecule.

Abstract: Methods and compositions are provided for identifying novel ligands for a protein target.

Abstract: Separation technologies and a support/separation phases for use therein. A surface of a support phase can be modified to include a crosslinked polymer network as stationary phase to perform separation of one or more species from a liquid in highly efficient separations based on chemical interactions, i.e., chromatography. Optionally, the support phase can employ polymer fibers having channels extending axially along their surfaces. The use of the support phase to support the crosslinked stationary phase can be used in one embodiment in the process of performing micro-scale separations.

Abstract: One aspect as reported herein is a method for detecting a rat antibody in a serum or plasma sample (obtained) from a mouse comprising the steps of a) providing the sample to be analyzed, b) incubating said serum or plasma sample with an antibody that specifically binds to rat IgG and that does not specifically bind to mouse IgG, wherein the antibody is i) a mixture of an antibody binding to rat kappa light chain and an antibody binding to rat lambda light chain, or ii) a mixture of an antibody binding to rat IgG1 with an avidity of 4.1×1010 M?1 or more, an antibody binding to rat IgG2a with an avidity of 8.6×109 M?1 or more, an antibody binding to rat IgG2b with an avidity of 6.4×1010 M?1or more and an antibody binding to rat IgG2c with an avidity of 9.

Abstract: Compositions and methods are provided for measuring the amount of GAS6 in a sample. Also provided are compositions and methods related to high-affinity CAS6 inhibitor agents that induce a conformational change of GAS6 that stabilizes Helix A of GAS6.

Abstract: The present invention provides a method of preparing a sample comprising one or more proteins of interest, the method comprising: providing a sample comprising a population of proteins of interest solubilised with a surfactant in a medium; exposing said sample to a mild precipitant to cause precipitation of said proteins; during or after the precipitation step, bringing said sample into contact with a matrix adapted to capture said precipitated proteins and prevent excessive aggregation of precipitated protein particles; and washing the matrix with captured precipitated proteins to remove the surfactant. A sample preparation device to carry out the same is also provided.

Abstract: A method for analyzing a component using a fluidic device. The method includes the steps of providing a distribution of the component across contacting first and second fluid flows; diverting a part of the first fluid flow, a part of the second fluid flow, or parts of the first fluid flow and the second fluid flow, wherein the diverted part includes the component; and analyzing the component in the diverted part of the fluid flow. Optionally the component may be labelled prior to the analyzing step. A flow apparatus for use in the method is also provided.

Abstract: A method of analyzing protein-protein interactions at a single molecular level is disclosed.

Abstract: The present invention provides biomarkers, methods and kits for diagnosing a Brucellosis, Q-Fever, and/or Lyme Disease, methods and kits for monitoring the effectiveness of treatment for Brucellosis, Q-Fever, or Lyme Disease, as well as methods for identifying a compound that can treat Brucellosis, Q-Fever, and/or Lyme Disease reduce or inhibit the development of complications associated with the disease in a subject, and methods to treat a Brucellosis, Q-Fever, and/or Lyme Disease.

Abstract: The invention provides methods for determining a set of critical features that serves as a “map” of attributes critical for maintaining the structure and function of a biologic. The map can serve as a development tool, e.g., as a guide or target during the development of expression, purification, and formulation protocols, a quality assurance tool during manufacturing, or as a definitive identifier of the specific biologic. The map can also serve as the definition of the biologic thereby providing a means by which a given product may be reliably characterized as a biosimilar of another biologic product.

Abstract: Methods, compositions, systems, and devices are provided for performing and analyzing agglutination assays. In one aspect, methods for image analysis of agglutination assays are provided. In another aspects, methods for performing agglutination assays are provided. In one aspect, the methods may be used for the detection of various molecules, including viruses or antibodies against a virus. In another aspect, the methods can be used to determine effective immunization of a subject.

Abstract: The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.

Abstract: Screening compounds by exposing a plurality of cardiomyocytes to a compound, wherein the cardiomyocytes express an optogenetic reporter of membrane potential and an optogenetic reporter of calcium level; receiving light from the optogenetic reporter of membrane potential; creating an AP waveform using the received light; and analyzing the AP waveform to determine the presence or absence of a risk for arrhythmia associated with the compound.

Abstract: A biological sensing device and a method for separating a biomolecule are provided. The biological sensing device includes an amino acid sequence and a signal-generating unit. The amino acid sequence includes SEQ ID NO: 1 or SEQ ID NO: 2, and is for binding with UlaG protein labeled on a biomolecule. The signal-generating unit connects to the amino acid sequence.

Abstract: The invention involves, inter alia, the use of markers of systemic inflammation to determine whether or not an individual undergoing treatment with a cardiovascular agent to reduce the risk of a future cardiovascular event will benefit from continued treatment with the cardiovascular agent. Further, this invention describes the use of markers of systemic inflammation to evaluate the efficacy of treatment and to assist physicians in deciding on the course of a treatment in an individual at risk of future cardiovascular events.

Abstract: The present invention relates to a method for diagnosing inflammatory bowel disease (IBD), the method comprising determining the concentration of at least one IBD-specific biomarker in a sample of the colonic mucocellular layer obtained from a subject.